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Correction to: British Journal of Cancer (2007) 96, 16–20.
doi: 10.1038/6603520
The authors would like to note that the preliminary results of a
phase II clinical trial of sorafenib in patients with metastatic
thyroid cancer reported as a personal communication in the
manuscript have been previously presented as part of the following
two abstract presentations:
Kloos R, Ringel M, Knopp M, Heverhagen J, Hall N Weldy L,
Arbogast D, Collamore M, Shah M (2005). Preliminary results of
Phase II clinical trial of RAF/VEGF-R kinase inhibitor, BAY 43-9006
(sorafenib), in metastatic thyroid carcinoma. Thyroid.2 0 0 5
Abstracts from International Thyroid Congress, Vol 15, No. S1:S-22.
Kloos R, Ringel M, Knopp M, Heverhagen J, Rittenberry J, Weldy
L, Arbogast D, Collamore M, King M, Young D, Shah M (2006).
Significant clinical and biologic activity of RAF/VEGF-R kinase
inhibitor BAY-439006 in patients with metastatic papillary thyroid
carcinoma (PTC): Updated results of a phase II study. J Clin Oncol,
2006 ASCO Annual Meeting Proceedings, Part I, Vol 24, No.
18S:5534.
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